使用肾素-血管紧张素系统和中性肽链内切酶抑制剂联合治疗新冠病毒病：我们找到解决方案了吗？ - Suppr

Treat or not treat COVID-19 with combined renin-angiotensin system and neprilysin inhibition: Have we found a solution?

作者信息

Emrich Insa E, Böhm Michael

机构信息

Department of Internal Medicine III, Cardiology, Angiology, and Intensive Care Medicine, Saarland University and Saarland University Medical Centre, Homburg, Germany.

出版信息

Eur J Heart Fail. 2025 Jan;27(1):148-151. doi: 10.1002/ejhf.3510. Epub 2024 Nov 19.

DOI:10.1002/ejhf.3510

PMID:39563085

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11798630/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c22c/11798630/150a38c0485a/EJHF-27-148-g001.jpg

相似文献

Treat or not treat COVID-19 with combined renin-angiotensin system and neprilysin inhibition: Have we found a solution?

Eur J Heart Fail. 2025 Jan;27(1):148-151. doi: 10.1002/ejhf.3510. Epub 2024 Nov 19.

Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.

Eur J Heart Fail. 2016 Oct;18(10):1238-1243. doi: 10.1002/ejhf.603. Epub 2016 Jun 30.

Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.

Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13.

The effect of neprilysin and renin inhibition on the renal dysfunction following ischemia-reperfusion injury in the rat.

Physiol Rep. 2021 Mar;9(6):e14723. doi: 10.14814/phy2.14723.

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.

BMC Pharmacol Toxicol. 2019 May 3;20(1):23. doi: 10.1186/s40360-019-0304-z.

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.

JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8.

Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.

Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14.

Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.

Biol Proced Online. 2020 Jun 19;22:11. doi: 10.1186/s12575-020-00124-6. eCollection 2020.

Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.

JACC Basic Transl Sci. 2022 Sep 7;8(1):88-105. doi: 10.1016/j.jacbts.2022.05.010. eCollection 2023 Jan.

[Angiotensin-neprilysin inhibition in ckd: does it confer a double benefit?].

Wiad Lek. 2019;72(11 cz 2):2228-2231.

本文引用的文献

Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trial.

Eur J Heart Fail. 2024 Jun;26(6):1393-1398. doi: 10.1002/ejhf.3199. Epub 2024 May 11.

Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial.

Eur J Heart Fail. 2023 Dec;25(12):2177-2188. doi: 10.1002/ejhf.3043. Epub 2023 Oct 9.

Effects of renin-angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials.

Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):68-80. doi: 10.1093/ehjcvp/pvad067.

Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.

J Am Heart Assoc. 2022 Sep 6;11(17):e026143. doi: 10.1161/JAHA.122.026143. Epub 2022 Aug 24.

Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.

Eur J Heart Fail. 2022 May;24(5):855-860. doi: 10.1002/ejhf.2490. Epub 2022 Mar 31.

A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.

Am Heart J. 2022 May;247:76-89. doi: 10.1016/j.ahj.2022.01.015. Epub 2022 Feb 7.

Long-term cardiovascular outcomes of COVID-19.

Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.

Eur Heart J. 2022 Mar 14;43(11):1033-1058. doi: 10.1093/eurheartj/ehab696.

Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial.

JACC Heart Fail. 2021 Sep;9(9):627-635. doi: 10.1016/j.jchf.2021.04.009. Epub 2021 Jul 7.

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.

Lancet Respir Med. 2021 Aug;9(8):863-872. doi: 10.1016/S2213-2600(21)00214-9. Epub 2021 Jun 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treat or not treat COVID-19 with combined renin-angiotensin system and neprilysin inhibition: Have we found a solution?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献